BIO

Nabanita Nawar is the CEO and co-founder of HDAX Therapeutics. Dr. Nawar played a lead role in building the foundational science behind HDAX during her PhD in Medicinal Chemistry at the University of Toronto. Her expertise in drug discovery, leadership, governance and science policy, fuels HDAX’s growth through her forward-thinking vision. Recognized as a Forbes 30 Under 30 honoree for Toronto in 2023, and Canada’s most prestigious BIOTECanada Next Generation Leadership Awardee 2023 for her leadership and innovation, Nabanita boasts an impressive portfolio that includes 10 high-impact publications, 2 patent applications, and over 20 awards and recognitions. These accolades include the Canadian Silver Medal from the Chemical Institute of Canada, The Society of Chemical Industry Merit Award, and the Top Scholar distinction at the University of Toronto. Under her leadership, HDAX has successfully raised >$1M USD to bring forth breakthrough therapies for unmet clinical needs. Nabanita is also a lecturer at the Temerty Faculty of Medicine of University of Toronto, for the Health Science Professional Master’s program.